Financing ·
RedHill Biopharma entered into a definitive agreement for a private placement of 8,571,429 ADSs and accompanying…
RDHLRedHill Biopharma Ltd.
RedHill Biopharma entered into a definitive agreement for a private placement of 8,571,429 ADSs and accompanying warrants, expected to close on June 22, 2026. The offering is priced at $0.70 per ADS, with expected upfront gross proceeds of approximately $6 million and potential additional gross proceeds of $13.4 million from the exercise of Series A-1 and A-2 warrants. RedHill Biopharma is a specialty biopharmaceutical company focused on the development and commercialization of drugs for gastrointestinal, infectious, and oncology diseases.